Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer
St-Laurent M, Singh P, McConkey D, Lucia M, Koshkin V, Stratton K, Bivalacqua T, Kassouf W, Porten S, Bangs R, Plets M, Thompson I, Meeks J, Caruso V, Ward C, Mazzarella B, Phillips K, Bicocca V, Levin T, Lerner S, Black P. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer. European Urology 2025 PMID: 40404526, DOI: 10.1016/j.eururo.2025.03.023.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerUrine tumor DNAEvent-free survivalTumor DNABladder cancerBCG-unresponsive NMIBCPatients treated with atezolizumabRisk of treatment failureClinical evidence of diseaseRisk of recurrenceEvidence of diseaseSystemic immunotherapyTreatment failureTherapeutic decisionsClinical evidencePatientsUrine samplesAtezolizumabBaselineCancerUrineTreatmentRiskImmunotherapySWOG
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply